There are ample data on the long-term durability of bioprosthetic surgical valves, with approximately 23% primary bioprosthetic valve failure rates at 15 years [
83]. Importantly, the age at which bioprosthetic SAVR is performed impacts the rate of bioprosthetic valve failure. Patients under 65 years of age who undergo bioprosthetic SAVR have a ~ 26% rate of bioprosthetic valve failure while those 65 years and older have a ~ 9% rate of this complication 15 years after valve implantation [
83]. The method of defining bioprosthetic valve failure is vital to understanding valve durability. The surgical literature defines bioprosthetic valve failure as patients who actually undergo surgical re-operation [
84]. In the era of valve-in-valve (ViV) TAVR, many patients with prohibitive surgical risk who would previously be declined for surgery, and thus not “counted” as bioprosthetic SAVR failure, are now being treated with ViV-TAVR. Data from the ViV International Database (VIVID) show that the average time from bioprosthetic SAVR to ViV-TAVR is 9 years [
85]. As more patients undergo ViV TAVR, our understanding of the durability of surgical bioprosthetic valves is likely to evolve. For THVs, long-term durability beyond 5–8 years is poorly understood and short-term durability appears similar between SEV and BEV [
86‐
88]. Unlike the definition of bioprosthetic valve failure in SAVR studies, there are numerous proposed methods of defining structural valve degeneration (SVD) and bioprosthetic valve failure after TAVR [
89]. SVD defined by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) is divided into mild, moderate, and severe based on the mean gradient, change in mean gradient from the initial post-procedural assessment, and degree of intra-prosthetic regurgitation [
90]. Bioprosthetic valve failure is defined as a THV with severe hemodynamic compromise either requiring intervention or causing death [
91]. The Valve Academic Research Consortium (VARC) criteria define severe structural valve dysfunction as a mean gradient > 40 mmHg (moderate to severe stenosis), EOAi < 0.6–0.65 cm
2/m
2 (severe patient prosthesis mismatch), DVI < 0.35, or moderate-to-severe prosthetic valve regurgitation [
91]. At 5–8 years THVs have a 3.6–10.8, 0–2.5, 0.6–7.5% for moderate SVD, severe SVD, and bioprosthetic valve failure, respectively [
92]. Numerous factors unique to TAVR can affect long-term durability including THV crimping, post-dilation, noncircular implantation, PVL, and leaflet thrombosis [
93]. Hypo-attenuating leaflet thickening (HALT) and hypo-attenuation affecting motion (HAM), both likely caused by leaflet thrombus formation, have been associated with SVD and post-TAVR stroke [
89,
94]. While less commonly seen in SAVR patients, HAM and HALT have been reported in up to 40% of TAVR [
95,
96].
A critical implication of bioprostheses durability is how the life-span of the valve compares to the life expectancy of the patient and the possibility of needing a second valve replacement. Indeed, in younger low-risk patients who have a > 15-year life expectancy, it is reasonable to consider implantation of a mechanical valve given the lower rate of mechanical aortic valve failure compared to surgical bioprosthetic valve failure [
81]. For failed bioprosthetic surgical valves, there is a growing body of data demonstrating the safety and short-term clinical efficacy of implanting a THV (TAV-in-SAV) [
97,
98]. Among patients in the TAV-in-SAV substudy of PARTNER 2 and CoreValve Pivotal Extreme risk trials, TAV-in-SAV 30-day mortality was approximately 2.6% with stable THV hemodynamics out to 3 years [
99‐
102]. TAV-in-SAV patients in the VIVID registry had a 5.3% overall mortality at 30 days [
103]. When TAV-in-SAV outcomes are compared to re-do SAVR, limited available data show comparable 30-day and 3-year mortality [
104,
105]. On the contrary, limited data exist on the treatment of a failed THV valve. Surgical removal and replacement of a failed THV can be a complex surgery potentially requiring aortic root replacement while the implantation of a second THV (TAV-in-TAV) has not been widely performed. A recent registry study found that 0.3% of TAVRs were TAV-in-TAV procedures done predominantly for valvular regurgitation with 2.9% overall mortality, low rates of stroke and coronary obstruction, but a 9% rate of ≥ moderate PVL [
106]. As TAVR patients continue to live longer, our understanding of long-term bioprosthetic valve durability will improve so we can better inform our decision on the best “first implanted valve” in younger, low-risk AS patients.